Business Context and Reporting Period
Company: Protagonist Therapeutics, Inc. (PTGX)
Filing Type: Form 8-K (Current Report)
Date of Report: August 4, 2021
Event: Entry into a Material Definitive Agreement resolving a dispute with Zealand Pharma A/S regarding post-termination payment obligations for the compound rusfertide.
Key Financial Metrics and Obligations
This filing details specific contractual payment obligations rather than general financial performance metrics (revenue, profit, cash flow) for the period.
- Immediate Cash Outflow: $2.5 million payable within 2 business days of the agreement effective date.
- $1.0 million for commencement of Phase 2b rusfertide trial.
- $1.5 million for initiation of Phase 3 rusfertide trial (expected Q1 2022).
- Future Fixed Payment: $1.5 million due in August 2022.
- Contingent Development Milestones: Up to $2.75 million potential future payments.
- Up to $1.0 million for registrational approvals (e.g., FDA NDA).
- Up to $1.75 million for commercial launch in the US, EU, and Rest of World.
- Contingent Sales Milestones: Up to $50 million aggregate based on net sales thresholds (reduced by 50% from original terms).
- Royalties: Reduced by 50% on net sales of rusfertide.
Material Changes and Dispute Resolution
The agreement resolves a long-standing dispute originating from a 2012 collaboration with Zealand Pharma that was abandoned in 2013. Protagonist had previously made $1.0 million in milestone payments believing rusfertide was subject to post-termination obligations, later disputing this in 2019 and initiating arbitration in 2020.
Key Changes to Original Terms:
- Royalty Rate: Reduced by 50%.
- Sales Milestones: Reduced by 50%.
- Development Milestones: Reduced by 50%, with the exception of the two immediate payments totaling $2.5 million which are payable in full.
- Legal Status: Arbitration proceedings are dismissed with prejudice; each party bears its own fees and costs.
Outlook, Risks, and Management Commentary
Outlook: The Company expects to initiate the rusfertide Phase 3 trial in the first quarter of 2022, triggering the $1.5 million milestone payment.
Risks and Contingencies:
- Liquidity Impact: Immediate requirement to pay $2.5 million plus a scheduled $1.5 million payment in August 2022.
- Future Liability: Potential exposure of up to $54.25 million in total future contingent payments (development and sales milestones) depending on clinical success and commercial performance.
- Scope: The agreement applies solely to rusfertide and does not affect other compounds.
Investor Verification Checklist
- Verify the Company's current cash and cash equivalents to assess the ability to fund the immediate $2.5 million payment and the $1.5 million payment due in August 2022.
- Confirm the timeline for the rusfertide Phase 3 trial initiation to validate the timing of the $1.5 million milestone payment.
- Review the full text of the Arbitration Resolution Agreement (to be filed as an exhibit to the Q3 2021 Form 10-Q) for detailed definitions of net sales thresholds and royalty calculations.
- Monitor clinical trial progress for rusfertide to assess the probability of triggering the remaining $2.75 million in development milestones.